MorphoSys takes over Sloning BioTechnology
The transaction is expected to make MorphoSys the sole source of Sloning’s Slonomics technology, which improves the assembly and quality of protein libraries. MorphoSys said that by integrating
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.